Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 3.1.2022 | EN | Official Journal of the European Union | C 2/33 |

---

Judgment of the General Court of 10 November 2021 — Stada Arzneimittel v EUIPO — Pfizer (RUXIMBLIS)

(Case T-542/20) [(1)](#ntr1-C_2022002EN.01003301-E0001)

(EU trade mark - Opposition proceedings - Application for the EU word mark RUXIMBLIS - Earlier EU word mark RUXIMERA - Relative ground for refusal - Likelihood of confusion - Similarity of the signs - Article 8(1)(b) of Regulation (EU) 2017/1001)

(2022/C 2/44)

Language of the case: English

Parties

Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)

Defendant: European Union Intellectual Property Office (represented by: T. Frydendahl, A. Folliard-Monguiral and D. Gája, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Pfizer Inc. (New York, New York, United States) (represented by: V. von Bomhard, J. Fuhrmann and P.-F. Karamolegkou, lawyers)

Re:

Action brought against the decision of the Fourth Board of Appeal of EUIPO of 16 June 2020 (Case R 1877/2019-4), relating to opposition proceedings between Pfizer and Stada Arzneimittel.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Stada Arzneimittel AG to pay the costs. |

---

---

[Top](#document1)